Condensed Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenues:
Revenues	$ 5,143	$ 5,685	$ 10,691	$ 10,966
Costs and expenses:
Cost of goods sold	1,064	1,000	2,033	1,957
Research and development expenses	1,299	995	2,303	1,926
Acquired in-process research and development expenses	4,524	165	4,621	291
Selling, general and administrative expenses	1,239	1,095	2,315	2,125
Total costs and expenses	8,126	3,255	11,272	6,299
Income (loss) from operations	(2,983)	2,430	(581)	4,667
Interest expense	(240)	(248)	(481)	(502)
Other income (expense), net	250	228	92	595
Income (loss) before provision for income taxes	(2,973)	2,410	(970)	4,760
Provision for income taxes	373	535	838	917
Net income (loss)	(3,346)	1,875	(1,808)	3,843
Net loss attributable to noncontrolling interest	(7)	(5)	(20)	(12)
Net income (loss) attributable to Gilead	$ (3,339)	$ 1,880	$ (1,788)	$ 3,855
Net income (loss) per share attributable to Gilead common stockholders - basic (usd per share)	$ (2.66)	$ 1.48	$ (1.42)	$ 3.03
Shares used in per share calculation - basic (in shares)	1,255	1,270	1,258	1,273
Net income (loss) per share attributable to Gilead common stockholders - diluted (usd per share)	$ (2.66)	$ 1.47	$ (1.42)	$ 3.01
Shares used in per share calculation - diluted (in shares)	1,255	1,277	1,258	1,280
Product sales
Revenues:
Revenues	$ 5,067	$ 5,607	$ 10,534	$ 10,807
Royalty, contract and other revenues
Revenues:
Revenues	$ 76	$ 78	$ 157	$ 159